|
 |
Volume 3, Number 11 (November 2006) | |||||
Letter from the Editor |
|||||
688 |
Pointing the way The West Clinic, Memphis, TN This month we focus in part on breast cancer with two major articles. The first is in our Community Translations section where we discuss the many aspects of the STAR trial (Study of Tamoxifen and Raloxifene). Starting with a cogent summary of the trial data, we offer commentary from a community oncologist, nurse, and practice administrator. The second article explores the role of MRI in breast imaging. Although this technology has assumed an important position in breast imaging, many questions remain.
|
||||
Community Translations |
|||||
699 |
The STAR results: choosing between raloxifene and tamoxifen for preventing invasive breast cancer in postmenopausal women The recently reported STAR trial (Study of Tamoxifen and Raloxifene) showed there was no significant difference in the incidence of invasive breast cancer in the two treatment groups. But their side effect profiles do differ. A roundup of the data, plus commentaries from a community oncologist, oncology nurse practitioner, and oncology practice administrator. | ||||
FROM THE COMMUNITY ONCOLOGIST'S PERSPECTIVE West Virginia University, Charleston Division, Charleston Area Medical Center, Charleston, WV | |||||
FROM THE NURSE'S PERSPECTIVE Aurora Health Care, Milwaukee, WI | |||||
FROM THE ADMINISTRATOR'S PERSPECTIVE Berks Hematology Oncology Associates, Ltd., Reading, PA
|
|||||
Community Dialogue |
|||||
704 |
Community oncology and cutting-edge research With the Molecular Profiling Institute of Phoenix, Arizona, US Oncology is creating a repository for the storage and genomic analysis of cancer tissue specimens. Dr. Dhir is overseeing the company’s clinical research and says that the ultimate objective of the project is to enable physicians to select targeted therapies for their patients. The project offers a chance for community oncologists to be involved in a higher level of clinical research, says Dr. Dhir.
|
||||
Implementing Clinical Trials |
|||||
709 |
The clinical network: a different approach Eli Lilly and Company, Indianapolis, IN The clinical network model offers a number of advantages over individual sites, including enhanced communication among investigators, administrative and technical support, and quality assurance. Included in this article is a sample list of questions to ask when selecting a network, as well as a brief discussion on signing agreements.
|
||||
Managing Side Effects |
|||||
719 |
Low-molecular-weight heparins in the prevention and management of malignancy-related venous thromboembolism Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA Venous thromboembolism (VTE) is a well-described and frequent complication of cancer and is the cause of significant patient morbidity and mortality. Low-molecular-weight heparins have demonstrated antithrombotic efficacy and safety in the prophylaxis and treatment of VTE. Recent clinical trials of these agents for secondary prophylaxis of VTE in cancer patients have demonstrated their superiority to warfarin. In addition, several clinical trials have suggested that they may impact the biology of cancer and improve survival, even in the absence of VTE. For these reasons, there is a growing interest in integrating low-molecular-weight heparins into the routine management of cancer patients with and without VTE.
|
||||
Controversies in Patient Management |
|||||
727 |
The role of MRI in breast imaging Curtis and Elizabeth Anderson Cancer Institute, Savannah, GA, and MRI at Belfair, Bluffton, SC Breast MRI is increasingly recommended before, during, and after neoadjuvant chemotherapy to evaluate tumor response. It is especially recommended for following high-risk patients with suspected or confirmed BRCA mutations. But MRI is not a substitute for screening mammography and is not indicated for the majority of women who are asymptomatic.
|
||||
Quality Care |
|||||
730 |
Treating elderly cancer patients: what you need to know about their physiology and specific medical needs Memorial Sloan-Kettering Cancer Center, New York, and Commack, NY By 2030, more than 20% of people in the United States will be aged 65 years or older. Approximately half of all cancers occur in this population; the disease is the second most common cause of death in this age group. Because life expectancy has increased tremendously over the past century and further increases are projected, the study of cancer and aging has emerged as a critical topic in oncologic care. This article outlines key issues in caring for the older adult with cancer and offers practitioners a better understanding of the differences in the physiology of these patients and their specific medical needs.
|
||||
Letters to the Editor |
|||||
695 |
When the pipeline becomes the bottom line Cancer Intelligence and Research, Virginia Beach, VA
|
||||
695 |
Serious doubts about faith Saint Louis, MO
|
||||
696 |
Get us out of this mess Cancer Center of North Dakota, Grand Forks, ND
|
||||
Technology |
|||||
716 |
Take a meeting—in cyberspace How can you get information out quickly to a group of patients, bring your fellow physicians together without inconveniencing them, or help out a colleague across the country? Meet in cyberspace. You probably already have all the tools you need.
| ||||
Washington Update |
|||||
725 |
A way through: five tactics for fixing overcorrected reimbursements With pending reductions in Medicare and practices across the country reporting losses, the Community Oncology Alliance proposes five concrete steps that must be taken now.
| ||||
© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
42 kb